Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*

D. Thaci, S. Piaserico, R. B. Warren, A. K. Gupta, W. Cantrell, Z. Draelos, P. Foley, A. Igarashi, R. G. Langley, A. Asahina, M. Young, M. Falqués, I. Pau-Charles, A. M. Mendelsohn, S. J. Rozzo, K. Reich

科研成果: 期刊稿件 › 文章 › 同行评审

64 引用 （Scopus）

指纹

探究 'Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*' 的科研主题。它们共同构成独一无二的指纹。

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Biochemistry, Genetics and Molecular Biology